FDA 483 - Taro Pharmaceuticals Inc. - September 16, 2022

An FDA inspection of Taro Pharmaceuticals Inc. in Brampton revealed significant deficiencies in manufacturing controls. The firm failed to establish adequate written procedures for in-process controls during packaging and did not consistently follow its own standard operating procedures for initiating and investigating deviations. These issues indicate a lack of robust quality system oversight.